Form 4: DocGo Director Leite Granted 150,000 RSUs

DocGo Inc. Director Etalvina Leite was granted 150,000 restricted stock units, vesting in December 2026, increasing her beneficial ownership to 201,411 shares.

Summary

• Etalvina Leite, a Director of DocGo Inc. (DCGO), acquired 150,000 shares of Common Stock.
• The transaction occurred on December 12, 2025, and represents a grant of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 per unit, indicating they are part of a compensation plan.
• The RSUs are granted pursuant to the Issuer's 2021 Stock Incentive Plan and will vest on December 12, 2026.
• Each RSU represents the right to receive one share of Common Stock upon vesting.
• Following this transaction, Etalvina Leite's beneficial ownership of DocGo Inc. Common Stock increased to 201,411 shares.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity compensation event for a director, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications or unexpected events.

Positives

• The grant of 150,000 Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule provides an incentive for long-term commitment and performance from the director.

Future Outlook

The 150,000 Restricted Stock Units granted to Director Etalvina Leite are scheduled to vest on December 12, 2026, subject to the terms of the company's 2021 Stock Incentive Plan.

Industry Context

The grant of Restricted Stock Units to directors is a common practice in publicly traded companies across various industries. It serves as a form of equity compensation designed to align the interests of the board members with those of the shareholders by tying a portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice, comparable to compensation structures observed in companies like Teladoc Health (TDOC) or Amwell (AMWL) within the telehealth and mobile health sectors.
• The vesting period of one year (from grant date to vesting date) is also a common structure for such grants, aiming to retain talent and incentivize sustained performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director is intended to align the director's interests with those of shareholders, potentially leading to decisions that enhance long-term stock value. It also represents a minor dilution upon vesting.
• Employees: No direct impact on general employees, but it reflects the company's compensation strategy for key personnel.

Next Steps

• The 150,000 Restricted Stock Units will vest on December 12, 2026, at which point they will convert into shares of DocGo Inc. Common Stock, subject to the terms of the 2021 Stock Incentive Plan.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is an expected corporate governance event. It does not provide new fundamental information that would significantly alter the company's valuation or outlook, thus a 'hold' recommendation is appropriate as it maintains the status quo regarding investment thesis.

Keywords

DocGo, DCGO, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Stock Incentive Plan